4/A: PharmaCyte Biotech Director Reports Stock Transaction
Insider Transaction (Form 4/A)
Jonathan Schechter, a Director of PharmaCyte Biotech, Inc., reported multiple transactions in common stock on March 31, 2026.
Summary
- Other acquisition/disposition: acquired 0 Stock Option (Right to Buy) on March 31, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Jonathan Schechter — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-03-31 | Other acquisition/disposition | Stock Option (Right to Buy) | 0 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-03-31 | Other acquisition/disposition (0 shares) |
Keywords
insider transaction, Form 4/A, PMCB, PharmaCyte Biotech, Inc., neutral, Jonathan Schechter
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.